Emergent BioSolutions Awarded 10-Year HHS Contract Valued at App

80
EBS: Emergent BioSolutions
2019-06-03 06:30:00
Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness - GlobeNewswire

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.